NTC
ACAD icon

NF Trinity Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

NF Trinity Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-205,000
Closed -$5.72M – 49
2017
Q2 		$5.72M Buy
+205,000
New +$6.11M 0.81% 28

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

NF Trinity Capital's ACAD Position: Q3 2017 in Review

NF Trinity Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2017, closing a stake of 205,000 shares — an estimated $5.72M sold.

NF Trinity Capital first reported a position in ACAD in Q2 2017 and held it in 1 quarter. The position peaked at $5.72M in Q2 2017. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

  • NF Trinity Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • NF Trinity Capital sold 205,000 Acadia Pharmaceuticals shares in Q3 2017, an estimated $5.72M.
  • NF Trinity Capital first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • NF Trinity Capital's Acadia Pharmaceuticals position peaked at $5.72M in Q2 2017.
  • 212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on NF Trinity Capital's 13F filing for Q3 2017, filed 7 Nov 2017.